The researchers compared anti-CGRP mAbs with other drugs for the prevention of episodic and chronic migraine using a likelihood to help versus harm analysis.
This study’s main goal was to investigate how ONS acts on patients’ protective mechanisms and pain-defending protective reﬂexes.
Atogepant is an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist.
The researchers’ goal was to provide an overview of endpoints and outcomes in the current acute migraine clinical trial literature to facilitate the development of novel treatments.
Study authors investigated differences between women who experience migraines 2 days before menstruation or the first 3 days of menstruation.
Liquid solution celecoxib may offer headache relief and improvements in functional disability in patients with migraine.
The purpose of this study was to evaluate the subsequent health resource utilization (HRU) of patients with migraine who received opioid medications at ED visits.
Study researchers assessed the brain connectivity patterns in the interictal phase of migraine and its relationship to migraine severity.
The researchers aimed to report a case of arachnoiditis as a complication of epidural blood patch (EBP) procedures and to systematically review the diagnostic workup, clinical outcomes, and treatment modalities reported in the literature.
Study investigators sought to determine if galcanezumab would reduce not only the frequency of migraine days but also the disabling nonpain symptoms of episodic and chronic migraine.